Sepracor

To see an up-to date selection of historical analyses and insights on Sepracor, visit our new, dynamically updated Company Summary report pages for Sepracor.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Sepracor are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Sepracor, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%   (Mylan)   (Invalid Date)
FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria   (Sanofi-Aventis)   (Invalid Date)
Sepracor Announces New Drug Submission (NDS) to Health Canada for STEDESA(TM) as Adjunctive Treatment for Epilepsy   (Sepracor)   (Invalid Date)
Sepracor Provides Update on Clinical Trials for SEP-225289 and LUNESTA(R) Pediatrics   (Sepracor)   (Invalid Date)
Perrigo Confirms That Its Partner Synthon Has Filed for Generic Version of Xyzal® Solution and Announcement of Lawsuit by Sepracor/UCB   (Perrigo)   (Invalid Date)
Sepracor's STEDESA(TM) (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA   (Sepracor)   (Invalid Date)
Glaxo and Sepracor put Lunivia to bed   (Sepracor)   (Invalid Date)
Sepracor Reports Preliminary Phase III Study Results for OMNARIS(R) HFA Nasal Aerosol in Seasonal Allergic Rhinitis   (Sepracor)   (Invalid Date)
Sepracor Announces Submission of STEDESA(TM) New Drug Application to FDA for Adjunctive Treatment of Epilepsy   (Sepracor)   (Invalid Date)
Sepracor Reports Preliminary Phase II Study Results for SEP-225441 for the Treatment of Generalized Anxiety Disorder   (Sepracor)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.